Gregorio Basile

Gregorio Basile

Auto-generated profile, based on publicly available information

Gregorio Basile

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2022 in Journal of Clinical Immunology
Verified
Journal Article
Open access
PDF file
MSMichele Spinicci
Michele Spinicci
AMAlessio Mazzoni
Alessio Mazzoni
MCMarco Coppi
Marco Coppi
AAAlberto Antonelli
Alberto Antonelli
LSLorenzo Salvati
Lorenzo Salvati
PPPaola Parronchi
Paola Parronchi
Purpose: SARS-CoV-2 infection in immunocompromised hosts is challenging, and prolonged viral shedding can be a common complication in these patients. We describe the clinical, immunological, and virological course of a patient with eosinophilic granulomatosis with polyangiitis, who developed the status of long-term asymptomatic SARS-CoV-2 carrier for more than 7 months. Methods: Over the study period, the patient underwent 20 RT-PCR tests for SARS-CoV-2 detection on nasopharyngeal swabs. In addition, viral cultures and genetic investigation of SARS-CoV-2 were performed. As for immunological assessment, serological and specific T-cell testing was provided at different time points. Results: Despite the patient showing a deep drug-induced B and T adaptive immunity impairment, he did not experience COVID-19 progression to severe complications, and the infection remained asymptomatic during the follow-up period, but he was not able to achieve viral clearance for more than 7 months. The infection was finally cleared by SARS-CoV-2-specific monoclonal antibody treatment, after that remdesivir and convalescent plasma failed in this scope. The genetic investigations evidenced that the infection was sustained by multiple viral subpopulations that had apparently evolved intra-host during the infection. Conclusion: Our case suggests that people with highly impaired B- and T-cell adaptive immunity can prevent COVID-19 progression to severe complications, but they may not be able to clear SARS-CoV-2 infection. Immunocompromised hosts with a long-term infection may play a role in the emergence of viral variants.

1 July 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
FLFilippo Lagi
Filippo Lagi
STSasha Trevisan
Sasha Trevisan
MPMatteo Piccica
Matteo Piccica
LGLucia Graziani
Lucia Graziani
GBGregorio Basile
Gregorio Basile
Alessandro BartoloniAlessandro Bartoloni
Alessandro Bartoloni
Evaluate the real-world accuracy of Myxovirus resistance protein A (MxA) detected by the rapid, point-of-care FebriDx test during the second-wave pandemic in Italy in patients with acute respiratory infection (ARI) and a clinical suspicion of COVID-19. Prospective, observational, diagnostic accuracy study whereby hospitalized patients with ARI were consecutively enrolled in a single tertiary care center in Italy from August 1, 2020 to January 31, 2021. COVID-19 was diagnosed in 136/200 (68.0%) patients and Non-COVID-19 was diagnosed in 64/200 (32.0%) patients. COVID-19 patients were younger and had a lower Charlson comorbidity index compared to Non-COVID-19 patients (p < 0.001). Concordance between FebriDx, MxA and rt-PCR for SARS-CoV-2 (gold standard) was good (k 0.93, 95% CI 0.87–0.99). Overall sensitivity and specificity were 97.8% [95% CI 93.7–99.5] and 95.3% [95% CI 86.9%–99.0%], respectively. FebriDx demonstrated a negative predictive value of 95.3% (95% CI 86.9–99.0) for an observed disease prevalence of 68%. FebriDx MxA showed high diagnostic accuracy to identify COVID-19 and could be considered as a real-time triage tool to streamline the management of suspected COVID-19 patients. FebriDx also detected bacterial etiology in Non-COVID-19 patients suggesting good performance to distinguish bacterial from viral respiratory infection.

Verified
Journal Article
Open access
PDF file
Guido GranataGuido Granata
Guido Granata
Nicola PetrosilloNicola Petrosillo
Nicola Petrosillo
LALucia Adamoli
Lucia Adamoli
MBMichele Bartoletti
Michele Bartoletti
Alessandro BartoloniAlessandro Bartoloni
Alessandro Bartoloni
OGon behalf of the ReCloDi (Recurrence of Clostridioides difficile Infection) Study Group
on behalf of the ReCloDi (Recurrence of Clostridioides difficile Infection) Study Group
Background: Limited and wide-ranging data are available on the recurrent Clostridioides difficile infection (rCDI) incidence rate. Methods: We performed a cohort study with the aim to assess the incidence of and risk factors for rCDI. Adult patients with a first CDI, hospitalized in 15 Italian hospitals, were prospectively included and followed-up for 30 d after the end of antimicrobial treatment for their first CDI. A case–control study was performed to identify risk factors associated with 30-day onset rCDI. Results: Three hundred nine patients with a first CDI were included in the study; 32% of the CDI episodes (99/309) were severe/complicated; complete follow-up was available for 288 patients (19 died during the first CDI episode, and 2 were lost during follow-up). At the end of the study, the crude all-cause mortality rate was 10.7% (33 deaths/309 patients). Two hundred seventy-one patients completed the follow-up; rCDI occurred in 21% of patients (56/271) with an incidence rate of 72/10,000 patient-days. Logistic regression analysis identified exposure to cephalosporin as an independent risk factor associated with rCDI (RR: 1.7; 95% CI: 1.1–2.7, p = 0.03). Conclusion: Our study confirms the relevance of rCDI in terms of morbidity and mortality and provides a reliable estimation of its incidence.

1 September 2020 in Minerva Endocrinology
Verified
Journal Article
Closed access
MPMatteo Piccica
Matteo Piccica
GBGregorio Basile
Gregorio Basile
FBFilippo Bartalesi
Filippo Bartalesi
GPGabriele Parenti
Gabriele Parenti
AFAlberto Farese
Alberto Farese
APAlessandro Peri
Alessandro Peri
Article: Tolvaptan efficacy and drug-drug interactions - Minerva Endocrinologica 2020 September;45(3):264-5 - Minerva Medica - Journals